Cargando…

Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women()

BACKGROUND: A 9-valent human papillomavirus (HPV6/11/16/18/31/33/45/52/58; 9vHPV) vaccine was developed to expand coverage of the previously developed quadrivalent (HPV6/11/16/18; qHPV) vaccine. METHODS: Efficacy, immunogenicity, and safety outcomes were assessed in Latin American participants enrol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruiz-Sternberg, Ángela María, Moreira, Edson D., Restrepo, Jaime A., Lazcano-Ponce, Eduardo, Cabello, Robinson, Silva, Arnaldo, Andrade, Rosires, Revollo, Francisco, Uscanga, Santos, Victoria, Alejandro, Guevara, Ana María, Luna, Joaquín, Plata, Manuel, Dominguez, Claudia Nossa, Fedrizzi, Edison, Suarez, Eugenio, Reina, Julio C., Ellison, Misoo C., Moeller, Erin, Ritter, Michael, Shields, Christine, Cashat, Miguel, Perez, Gonzalo, Luxembourg, Alain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887018/ https://www.ncbi.nlm.nih.gov/pubmed/29269325 http://dx.doi.org/10.1016/j.pvr.2017.12.004

Ejemplares similares

Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age
por: Moreira, E. D., et al.
Publicado: (2017)

Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up
por: Olsson, Sven-Eric, et al.
Publicado: (2020)

Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries
por: Garland, S M, et al.
Publicado: (2018)

Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials
por: Petersen, Lone K., et al.
Publicado: (2017)

Cutaneous HPV and alpha-mucosal 9-valent HPV sero-status associations
por: Rahman, Shams, et al.
Publicado: (2017)

Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
por: Garland, Suzanne M., et al.
Publicado: (2022)

Development and Validation of Two Optimized Multiplexed Serologic Assays for the 9-Valent Human Papillomavirus Vaccine Types
por: Nolan, Katrina M., et al.
Publicado: (2023)

Letter to the Editor Regarding: “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
por: Gomez, Jorge A., et al.
Publicado: (2022)

On the Automaticity of the Evaluative Priming Effect in the Valent/Non-Valent Categorization Task
por: Spruyt, Adriaan, et al.
Publicado: (2015)

Burden of varicella in Latin America and the Caribbean: findings from a systematic literature review
por: Arlant, Luiza Helena Falleiros, et al.
Publicado: (2019)

Botryoid Rhabdomyosarcoma of the Conjunctiva in a Young Boy
por: Pennington, Justin D., et al.
Publicado: (2018)

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial
por: Thiem, Vu Dinh, et al.
Publicado: (2021)

Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up
por: Kjaer, Susanne K., et al.
Publicado: (2020)

Response to article by Johnna Perdrizet et al.,“Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants”
por: Gómez, Jorge A., et al.
Publicado: (2021)

Seroprevalence and Associated Factors of 9-Valent Human Papillomavirus (HPV) Types among Men in the Multinational HIM Study
por: Rahman, Shams, et al.
Publicado: (2016)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
por: Earnshaw, Stephanie R, et al.
Publicado: (2012)

Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly
por: Kislaya, Irina, et al.
Publicado: (2019)

Spotlight on the 9-valent HPV vaccine
por: Lopalco, Pier Luigi
Publicado: (2016)

Otitis media in children vaccinated during consecutive 7-valent or 10-valent pneumococcal conjugate vaccination schedules
por: Leach, Amanda Jane, et al.
Publicado: (2014)

Assessment of Health Benefits and Cost-Effectiveness of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccination in Kenyan Children
por: Ayieko, Philip, et al.
Publicado: (2013)

Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico
por: Wasserman, Matthew, et al.
Publicado: (2018)

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
por: Hanquet, Germaine, et al.
Publicado: (2022)

Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
por: Haggenburg, Sabine, et al.
Publicado: (2023)

1394. Impact of 7-Valent and 13-Valent Pneumococcal Conjugate Vaccines in the United States: A Systematic Literature Review
por: Kistler, Kristin, et al.
Publicado: (2020)

Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
por: Perdrizet, Johnna, et al.
Publicado: (2021)

Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
por: Dhere, Rajeev, et al.
Publicado: (2022)

A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries
por: Martí, Sebastián García, et al.
Publicado: (2013)

Dialkyl Ether Formation at High-Valent Nickel
por: Le Vaillant, Franck, et al.
Publicado: (2020)

On the existence of low-valent magnesium–calcium complexes
por: Mai, Jonathan, et al.
Publicado: (2023)

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years
por: Maldonado, Ivette, et al.
Publicado: (2022)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
por: Shiramoto, Masanari, et al.
Publicado: (2015)

Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada
por: Wilson, Michele, et al.
Publicado: (2018)

Comparison of enhancement of anaerobic digestion of waste activated sludge through adding nano-zero valent iron and zero valent iron
por: Wang, Yayi, et al.
Publicado: (2018)

P1523: IMMUNOGENICITY OF THE 13-VALENT PNEUMOCOCCAL CONJUGATED VACCINE FOLLOWED BY THE 23-VALENT POLYSACCHARIDE VACCINE IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Haggenburg, Sabine, et al.
Publicado: (2023)

Boy
por: Coloma, Luis, 1851-1915
Publicado: (1957)

Boy
por: Coloma, Luis, 1851-1915
Publicado: (1973)

Boy
Publicado: (1980)

On Boys
Publicado: (1870)

How Do Nutritional Warnings Work on Commercial Products? Results From a Hypothetical Choice Experiment
por: de Alcantara, Marcela, et al.
Publicado: (2022)

Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults
por: Belmonti, Simone, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_io4304idqv9sabol9esh95t7bf